ArticleHuman vaccines & immunotherapeutics2025
Development and characterization of a bivalent mRNA vaccine targeting the Delta and Omicron variants of SARS-CoV-2.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of the Omicron variant of SARS-CoV-2 has led to a decrease in vaccine efficacy and contributed to the ongoing epidemic of COVID-19. Consequently, there is an urgent need to develop new vaccines targeting the emerging SARS-CoV-2 variants. To address this, we developed a bivalent mRNA vaccine, ARCoV-Biv, targeting the receptor-binding domains (RBDs) of Delta and Omicron BA.1 variants, which were selected for their strong transmissibility and immune escape potential, necessitating an updated vaccine formulation for broader protection. In vitro characterization showed that ARCoV-Biv exhibited favorable physicochemical properties comparable to the monovalent mRNA vaccines. Then, the immunogenicity of the vaccine candidates under a two-dose prime immunization regimen were further analyzed, demonstrating that ARCoV-Biv induced a broad neutralizing antibody response, with mean neutralization titers (NT50) of 87,556.33 against Delta (B.1.617.2) and 52,634.67 against Omicron BA.1, representing 71.19-fold and 399.72-fold increases, respectively, compared to the levels prior to booster immunization. It also elicited robust cellular immunity against different variants. Furthermore, the booster effect of ARCoV-Biv following the administration of two doses of ARCoV (prototype vaccine) was evaluated. The results showed that ARCoV-Biv significantly enhanced the neutralizing activity of immunized serum against BA.2.12.1 (5,700.67) and BA.4/5 (1,289.5) in addition to the prototype, Delta, and BA.1 variants. These findings suggest that ARCoV-Biv may serve as a foundational platform for future vaccine optimization against newly emerging SARS-CoV-2 strains. Compared to mRNA-1273.214 (Moderna), a bivalent vaccine, ARCoV-Biv demonstrated a higher neutralization breadth against Delta and Omicron BA.1, along with enhanced T-cell responses, indicating potential advantages in cross-variant protection and durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.